Celltrion

Main menu

Biosimilars

Renew your life and happiness Refresh your possibilities and opportunities

What are biosimilars?

Biosimilars are laboratory-generated clones of high-priced Biologics. Having the same structure as their parent biologics, biosimilars provide the same pharmaceutical effects at affordable prices, improving access to medical treatments patients need. Biosimilars are a new paradigm of therapeutic agents that have revolutionized the social economy.

The benefits of biosimilars

Biosimilar - PATIENT, GOVERNMENT, INDUSTRY

PATIENT Enhanced opportunity to receive therapy and improve Quality of Life

Biosimilars enable patients to receive the same treatment as high-priced Biologics but at more reasonable prices. The decrease in medical expense not only improves patient access to treatments they need, but also provides patients the chance to use the opportunity cost to enrich the quality of their lives.

Price comparison of various products used in the treatment of rheumatoid arthritis

- Remsima
(Infliximab)
Enbrel
(Etanercept)
Humira
(Adalimumab)
Price 363,530 KRW/vial
(100mg)
149,439 KRW/PFS
(50mg)
422,775 KRW/PFS
(40mg)
Dose 3㎎/㎏ 1PFS per Dose 1PFS per Dose
Number of Administrations Required per Year (Maintenance Therapy) 8 Times 52 Times 26 Times
Medication Cost per Dose (Remsima 60 kg, Enbrel and Humira in Adult Standard) 727,060 KRW 149,439 KRW 422,775 KRW
Annual Medication Cost 5,816,480 KRW 7,770,828 KRW 10,992,150 KRW

GOVERNMENT Financial Burden is lowered while the number of beneficiaries is increased

Biosimilars decrease the medical expenditure of individual patients, while also lowering government financial burden by decreasing costs in the medical science field and heightening the number of medical insurance beneficiaries. Research by IMS, an investigation institute specialized for global market research, has shown that total global medical expenditure will be reduced by a maximum of 110 billion dollars (approx. 128 trillion KRW) by the year 2020 due to the entry of biosimilars.

Policies supporting Biosimilar research in developed countries

In many developed countries around the globe, policies supporting Biosimilar research are being established with the purpose of lowering government financial burden in terms of medication costs.

Denmark

RADS (Rådet for Anvendelse af Dyr Sygehusmedin: Council for Governing the Use of High-priced Medicine and Medical Supplies in Hospitals) has advised medical practitioners in Denmark to begin prescribing Biosimilars simultaneously with the original Biologics to all their patients.

Norway

The Norwegian government is granting 233 million dollars to support clinical research investigating methods to replace original Biologics with Biosimilars in order to lower the total medical expenditure of the nation. What is notable is that, through LIS (Norwegian drug procurement cooperation), the Norwegian government has replaced original Biologics with Biosimilars as their official choice of medication in indications where these therapies are particularly efficacious including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. The NoMa (The Norwegian Medicines Agency) foresees that by the end of 2016, Biosimilars will have completely replaced original Biologics in Norway.

Great Britain

NICE (National Institute for Health and Care Excellence) has recently made an amendment to its guidelines on the use of Biologics for the treatment of rheumatoid arthritis which advises hospitals to consider the Biosimilar, Remsima, as their first choice in prescription. Currently, several countries rely on NICE guidelines when deciding the standard insurance premium.

Finland

In 2015, the Finnish government stated that they recommend the interchangeability of Biosimilars which have been approved by the European Union.

United States

The United States is preparing legislation encouraging the development of Biosimilars even though most developers for original Biologics are concentrated in this country. The U.S. guarantees a 1-year period of monopoly to the first Biosimilar that has been FDA-approved through the enactment of the Biologics Price Competition & Innovation Act. In addition, the U.S. government is developing legislation for resolving patent disputes between developers of original Biologics and of Biosimilars in order to lessen the major barrier for market release of Biosimilars.

France

It is now possible to substitute Biosimilars for prescribed original Biologics in France as the government has proposed and passed legislation regarding the use of Biosimilars which meet specific standards and are, hence, legally approved.

Hungary

Since 2012, Hungary has been putting into effect law to meet quotas of Biosimilars. The Hungarian government has also stated that they are looking into ways of developing legislation for giving incentives to the medical institutions that use Biosimilars through the White Book on Physical and Rehabilitation Medicine in Europe (2011).

Germany

The government in Germany provides training on the use of biosimilars to medical practitioners as a part of their enforcement on policies supporting Biosimilars. Certain parts of Germany have implemented a biosimilar quota system in order to increase uptake of biosimilars in the country. According to the statement from DVFA (Die Vereinigung: the Society of Investment Professionals in Germany), such policies will lead to a decrease in government financial burden with respect to the production of Biologics by as much as 2 trillion KRW (13%) by the year 2020.

The Effects of Using Biosimilars on Medication Costs and Medical Insurance Rates

European and other developed countries are planning to reinforce the Biosimilars market in line with the increasing aging population and chronic illnesses they suffer from. Based on research data, it is likely that Biosimilars are going to help reduce the global medication expenditure by a maximum of 108 billion dollars (116 trillion KRW) within the next decade.

The predicted reduction in medication costs during the first year of using Remsima
(Unit: Million EUR)
- Rheumatoid arthritis Ankylosing spondylitis Crohn’s disease Ulcerative colitis Psoriatic arthritis Psoriasis Total
Germany 1.724 2.432 17.908 6.337 3.722 1.675 33.798
UK 1.792 0.569 6.353 0.980 0.554 0.614 10.862
Italy 1.937 2.032 2.203 2.795 2.902 2.009 13.878
The Netherlands 0.772 0.706 5.353 2.900 0.304 0.131 10.167
Belgium 0.720 0.711 4.028 2.431 0.518 0.254 8.662
Total 6.944 6.451 35.846 15.443 8.000 4.682 77.367
The number of additional patients who can be treated with Remsima as a result of the reduction in medication cost
(unit: number of people)
- Rheumatoid arthritis Ankylosing spondylitis Crohn’s disease Ulcerative colitis Ulcerative colitis Psoriasis Total
Germany 219 159 1358 472 268 126 2602
UK 362 60 762 117 64 72 1436
Italy 324 195 247 305 306 208 1583
The Netherlands 122 58 503 253 27 12 976
Belgium 132 67 440 244 54 27 964
Total 1158 538 3309 1392 718 446 7561

INDUSTRY The Next Generation Growth Engine for Korea

Biosimilar research has opened up a new horizon for the pharmaceutical industry in Korea as Biosimilars will allow advancement into the global market. Hence, Biosimilars are the next generation growth engine as well as a potential high-value industry in Korea following closely behind the electronics and IT industries.

The Growth Rate Comparison between Biologics and Biosimilars

Biologics have become the center of attention in the pharmaceutical industry around the globe. In line with this trend, it is predicted that the market size for Biosimilars will expand to approximately 24 billion dollars (28 trillion KRW) with a 60% increase per year growth until the year 2019.

The Top 10 Global Blockbuster Pharmaceuticals and their Sales
Biologics Chemically Synthesized Pharmaceuticals
(Unit: Million EUR)

2004

  • Lipitor 10,862
  • Zocor 5,197
  • Seretide/Advair 4,474
  • Norvasc 4,463
  • Zyprexa 4,420
  • Nexium 3,883
  • Procrit 3,589
  • Zoloft 3,361
  • Effexor 3,347
  • Plavix 3,327

2006

  • Lipitor 13,801
  • Seretide/Advair 6,182
  • Plavix 6,057
  • Enbrel 4,476
  • Remicade 4,428
  • Zyprexa 4,364
  • Diovan 4,287
  • Risperdal 4,183
  • Aranesp 4,121
  • Rituxan 3,864

2008

  • Lipitor 13,507
  • Plavix 9,451
  • Seretide/Advair 7,749
  • Enbrel 6,454
  • Remicade 6,240
  • Diovan 5,825
  • Rituxan 5,487
  • Nexium 5,200
  • Abilify 5,122
  • Avastin 4,823

2010

  • Lipitor 11,968
  • Plavix 9,429
  • Remicade 8,031
  • Seretide/Advair 8,023
  • Enbrel 7,257
  • Abilify 6,845
  • Humira 6,666
  • Avastin 6,216
  • Diovan 6,126
  • Rituxan 6,115

2012

  • Humira 9,616
  • Remicade 9,105
  • Enbrel 8,496
  • Abilify 8,135
  • Seretide/Advair 8,062
  • Rituxan 7,156
  • Crestor 6,714
  • Lantus 6,378
  • Herception 6,283
  • Avastin 6,150

2014

  • Humira 12,816
  • Sovaldi 10,283
  • Remicade 9,885
  • Enbrel 8,915
  • Lantus 8,428
  • Rituxan 7,546
  • Avastin 7,018
  • Seretide/Advair 7,018
  • Herception 6,863
  • Crestor 5,911
Analysis of the Global Biosimilars Market
위로 가기